Voxilaprevir: Difference between revisions
Content deleted Content added
clean up, rmv redlink portal |
Ozzie10aaaa (talk | contribs) m Cleaned up using AutoEd |
||
(10 intermediate revisions by 8 users not shown) | |||
Line 1: | Line 1: | ||
{{short description|Protease inhibitor}} |
|||
{{Use dmy dates|date=January 2020}} |
{{Use dmy dates|date=January 2020}} |
||
{{Infobox drug |
{{Infobox drug |
||
| drug_name = |
| drug_name = |
||
| type = |
| type = |
||
| IUPAC_name = (1''R'',18''R'',20''R'',24''S'',27''S'',28''S'')-''N''-[(1''R'',2''R'')-2-(Difluoromethyl)-1-<nowiki>{[(</nowiki>1-methylcyclopropyl)sulfonyl]carbamoyl |
| IUPAC_name = (1''R'',18''R'',20''R'',24''S'',27''S'',28''S'')-''N''-[(1''R'',2''R'')-2-(Difluoromethyl)-1-<nowiki>{[(</nowiki>1-methylcyclopropyl)sulfonyl]carbamoyl}cyclopropyl]-28-ethyl-13,13-difluoro-7-methoxy-24-(2-methyl-2-propanyl)-22,25-dioxo-2,21-dioxa-4,11,23,26-tetraazapentacyclo[24.2.1.0<sup>3,12</sup>.0<sup>5,10</sup>.0<sup>18,20</sup>]nonacosa-3(12),4,6,8,10-pentaene-27-carboxamide |
||
| image = Voxilaprevir.svg |
| image = Voxilaprevir.svg |
||
| alt = |
| alt = |
||
| caption = |
| caption = |
||
<!-- Clinical data --> |
<!-- Clinical data --> |
||
| pronounce = |
| pronounce = |
||
| tradename = Vosevi (combination with [[sofosbuvir]] and [[velpatasvir]]) |
| tradename = Vosevi (combination with [[sofosbuvir]] and [[velpatasvir]]) |
||
| Drugs.com = |
| Drugs.com = |
||
| MedlinePlus = |
| MedlinePlus = |
||
| licence_EU = |
| licence_EU = |
||
| licence_US = |
| licence_US = |
||
| pregnancy_AU = <!-- A/B1/B2/B3/C/D/X --> |
| pregnancy_AU = <!-- A/B1/B2/B3/C/D/X --> |
||
| pregnancy_AU_comment = |
| pregnancy_AU_comment = |
||
| pregnancy_US = <!-- A/B/C/D/X/N --> |
| pregnancy_US = <!-- A/B/C/D/X/N --> |
||
| pregnancy_category = |
| pregnancy_category = |
||
| routes_of_administration = |
| routes_of_administration = |
||
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled--> |
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled--> |
||
| legal_AU_comment = |
| legal_AU_comment = |
||
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII --> |
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII --> |
||
| legal_DE = <!-- Anlage I, II, III --> |
| legal_DE = <!-- Anlage I, II, III --> |
||
Line 29: | Line 30: | ||
| legal_status = <!-- Free text --> |
| legal_status = <!-- Free text --> |
||
<!-- Pharmacokinetic data --> |
<!-- Pharmacokinetic data --> |
||
| bioavailability = |
| bioavailability = |
||
| protein_bound = |
| protein_bound = |
||
| metabolism = |
| metabolism = |
||
| metabolites = |
| metabolites = |
||
| onset = |
| onset = |
||
| elimination_half-life = |
| elimination_half-life = |
||
| duration_of_action = |
| duration_of_action = |
||
| excretion = |
| excretion = |
||
<!-- Identifiers --> |
<!-- Identifiers --> |
||
| CAS_number = 1535212-07-7 |
| CAS_number = 1535212-07-7 |
||
| PDB_ligand = L9P |
| PDB_ligand = L9P |
||
| class = |
| class = |
||
| ATCvet = |
| ATCvet = |
||
| ATC_prefix = <!-- 'none' if uncategorised --> |
| ATC_prefix = <!-- 'none' if uncategorised --> |
||
| ATC_suffix = |
| ATC_suffix = |
||
| PubChem = 89921642 |
| PubChem = 89921642 |
||
| DrugBank = |
| DrugBank = |
||
| ChemSpiderID = 44209500 |
| ChemSpiderID = 44209500 |
||
| UNII = 0570F37359 |
| UNII = 0570F37359 |
||
Line 58: | Line 59: | ||
}} |
}} |
||
'''Voxilaprevir''' is a [[hepatitis C virus]] (HCV) nonstructural (NS) protein [[NS3 (HCV)|3]]/[[NS4A|4A]] protease inhibitor (by [[Gilead Sciences|Gilead]]) that is used in combination with [[sofosbuvir]] and [[velpatasvir]]. The combination has the trade name [[Vosevi]] and received a positive opinion from the European [[Committee for Medicinal Products for Human Use]] in June 2017.<ref>{{cite web|url=http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/004350/WC500229884.pdf|publisher=[[European Medicines Agency]]|title=Summary of opinion: Vosevi|date=22 June 2017}}</ref> |
'''Voxilaprevir''' is a [[hepatitis C virus]] (HCV) nonstructural (NS) protein [[NS3 (HCV)|3]]/[[NS4A|4A]] protease inhibitor (by [[Gilead Sciences|Gilead]]) that is used in combination with [[sofosbuvir]] and [[velpatasvir]].<ref name="Heo_2018">{{cite journal | vauthors = Heo YA, Deeks ED | title = Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C | journal = Drugs | volume = 78 | issue = 5 | pages = 577–587 | date = April 2018 | pmid = 29546556 | doi = 10.1007/s40265-018-0895-5 | s2cid = 4395880 }}</ref> The combination has the trade name [[Vosevi]] and received a positive opinion from the European [[Committee for Medicinal Products for Human Use]] in June 2017.<ref>{{cite web|url=http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/004350/WC500229884.pdf|publisher=[[European Medicines Agency]]|title=Summary of opinion: Vosevi|date=22 June 2017}}</ref> |
||
On 18 July 2017, Vosevi was approved by [[Food and |
On 18 July 2017, Vosevi was approved by the US [[Food and Drug Administration]].<ref>[https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm567467.htm FDA approves Vosevi for Hepatitis C]</ref> |
||
==References== |
==References== |
Latest revision as of 16:37, 28 January 2023
Clinical data | |
---|---|
Trade names | Vosevi (combination with sofosbuvir and velpatasvir) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
PDB ligand | |
Chemical and physical data | |
Formula | C40H52F4N6O9S |
Molar mass | 868.94 g·mol−1 |
3D model (JSmol) | |
Density | 1.4±0.1[1] g/cm3 |
| |
|
Voxilaprevir is a hepatitis C virus (HCV) nonstructural (NS) protein 3/4A protease inhibitor (by Gilead) that is used in combination with sofosbuvir and velpatasvir.[2] The combination has the trade name Vosevi and received a positive opinion from the European Committee for Medicinal Products for Human Use in June 2017.[3]
On 18 July 2017, Vosevi was approved by the US Food and Drug Administration.[4]
References[edit]
- ^ "voxilaprevir_msds".
- ^ Heo YA, Deeks ED (April 2018). "Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C". Drugs. 78 (5): 577–587. doi:10.1007/s40265-018-0895-5. PMID 29546556. S2CID 4395880.
- ^ "Summary of opinion: Vosevi" (PDF). European Medicines Agency. 22 June 2017.
- ^ FDA approves Vosevi for Hepatitis C